PharmExtracta

What PharmExtracta does

PharmExtracta S.p.A. is an Italian pharmaceutical company headquartered in Pontenure (Piacenza) that develops and markets clinically validated nutraceutical food supplements and CE-marked medical devices. Formed through the merger of Omeopiacenza S.r.l. and PharmExtracta S.r.l. and operating for more than 30 years, the company applies pharmaceutical-grade R&D discipline to botanical and probiotic products organized across three commercial lines: Biofarmaceutica (clinical-grade nutraceutical and botanical formulations), Metabolic Care (glycemic, lipid, and metabolic syndrome products), and Bacterial Care (precision probiotics and psychobiotics).

The portfolio spans roughly 20 branded products (Berberol®, Sophy®, Crispact®, Brevicillin®, Gabapral®, Butirrisan®, Fibradis®, Neurofast®, Emospid®, Dispepril®, Mirgeal®, Meloff®, MonoSelect® Agnus, MonoSelect® Macrocarpon, Nisatol®, Hepa G®, Quevir®, Bactorinol®, Zantogin® Gel, Kramegin®) targeting gynecology, gastroenterology, cardio-metabolic health, pediatrics, ENT, oncology, immunology, and urology. The technology foundation rests on a proprietary Phytosome® phospholipid-based delivery platform that meaningfully improves botanical bioavailability (berberine approximately 10x), a multi-layer tablet technology that combines normal, fast, and 8-hour slow-release profiles in a single unit, enteric coating for intestinal-targeted delivery, and a portfolio of proprietary typed probiotic strains identified through academic research partnerships. The company holds 40 active patents and reports more than 170 scientific publications (Italian site cites over 200).

Commercially, PharmExtracta operates a B2B model centered on healthcare professionals (gynecologists, pediatricians, gastroenterologists, ENTs, cardiologists, urologists, GPs) through direct field sales and medical education programs (PharmExtracta Campus with FAD-accredited webinars, podcasts, in-person events) in Italy. International expansion is executed via regional distribution partnerships, with HOA BINH BUSINESS AND DEVELOPMENT JSC serving as the launch partner for the Vietnamese market and the Bactorinol® nasal spray format introduced for international markets in 2024-2025. Revenue is generated primarily through one-time sales of food supplements and medical devices to clinicians, pharmacies, and distribution partners; pricing is not publicly disclosed. The company is privately held under Italian S.p.A. corporate structure with no external funding rounds or parent-company ownership disclosed.

Name

PharmExtracta

Legal name

PharmExtracta S.p.A.

Website

https://pharmextracta.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

51–100 employees

Short description

PharmExtracta S.p.A. is an Italian nutraceutical and medical device company that develops clinically validated food supplements, precision probiotics, and botanical formulations, distributed primarily through healthcare professionals in Italy and via regional distribution partners internationally, with 40 active patents and 170+ scientific publications.

Ownership category

akta.pro rank

Product category

Nutraceuticals and pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

akta.pro secondary industries

Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Phytotherapy products
• Precision probiotics
• Nutraceutical formulations
• Botanical supplements
• Medical devices

Headquarters

HQ city

Pontenure

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Food Supplements (Nutraceuticals): PharmExtracta's primary revenue stream comprises food supplements across three product lines: Biopharmaceuticals (optimizing pharmacological and clinical yield of nutraceutical substances and botanicals), Metabolic Care (innovative formulations for metabolic management), and Bacterial Care (probiotics and bioprotics). Products include Berberol®, Sophy®, Crispact®, Gabapral®, Brevicillin®, Butirrisan®, Fibradis®, Nisatol®, MonoSelect® Agnus, MonoSelect® Macrocarpon, Neurofast®, Dispepril®, Emospid®, Hepa G®, Meloff®, Mirgeal®, Quevir®, and Zantogin® Gel. Distributed primarily through healthcare professional channels and international distributors.
2. Medical Devices: Certain products are classified as medical devices, including Bactorinol® (nasal drops and spray based on Winterized Lentisk Oil for chronic rhinosinusitis), Zantogin® Gel (vaginal gel for genitourinary syndrome of menopause), and Kramegin® Vaginal Douche. These products undergo MDR regulatory pathways and generate revenue through medical device distribution channels targeting healthcare providers and patients.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

PharmExtracta S.p.A. develops, manufactures, and distributes clinically validated food supplements (botanical phytotherapeutics and precision probiotics) and medical devices organized across three lines: Biofarmaceutica, Metabolic Care, and Bacterial Care. Its products are built on proprietary delivery platforms including Phytosome® phospholipid technology, multi-layer differentiated-release tablets, enteric coating, and a patented prebiotic fiber blend, and incorporate proprietary typed probiotic strains. The portfolio is sold primarily through healthcare professionals in Italy and selected international distributor partners across eight therapeutic areas.

Product overview

PharmExtracta S.p.A. is an Italian pharmaceutical company applying drug development rigor to a portfolio of food supplements and medical devices organized across three product lines: Biofarmaceutica (optimizing nutraceutical and botanical efficacy), Metabolic Care (metabolic health formulations), and Bacterial Care (probiotics and bioprotics). The company holds 40 active patents and 170+ scientific publications. The product portfolio includes precision probiotics (Crispact® with Lactobacillus crispatus M247, Brevicillin®, Gabapral®, Butirrisan®), botanical supplements (Sophy® with Berberine Phytosome®, Berberol®, Nisatol®, MonoSelect® Agnus, MonoSelect® Macrocarpon), biopharmaceuticals (Neurofast®, Mirgeal® gel, Emospid®, Dispepril®, Meloff®), medical devices (Bactorinol® nasal spray/drops, Zantogin® Gel, Kramegin®), and liver health products (Hepa G®). Products are distributed across therapeutic areas including gastroenterology, gynecology, pediatrics, cardio-metabolic health, oncology, immunology, and urology.

Differentiator

Problem solved

Functional benefit

Brands

• Biofarmaceutica: Product line that optimizes pharmacological and clinical yield of nutraceutical substances and botanical derivatives
• Metabolic Care
• Bacterial Care

Products and services

• Crispact®

Quantifiable outcome

• Berberol® reduces LDL cholesterol by 25% as monotherapy, 28% as add-on to statins, 33% as add-on to ezetimibe
• +13 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• HOA BINH BUSINESS AND DEVELOPMENT JSCcoreChannel Partner/ Reseller/ DistributorHOA BINH BUSINESS AND DEVELOPMENT JSC is PharmExtracta's exclusive distribution partner for the Vietnamese market. The partnership was established to launch Fibradis® in Asia, beginning with Vietnam. Dr. Bac Nguyen and his team at HOA BINH lead the regional market development. The partnership represents PharmExtracta's strategic expansion into the Asian nutraceutical market.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Metagenics: Global clinical-grade nutritional products company positioned around evidence-based supplements across metabolic, gastrointestinal, and women's health categories. Comparable HCP-driven, science-forward positioning to PharmExtracta's portfolio.
• Specchiasol: Italian natural medicine company focused on botanical and phytotherapeutic products distributed through pharmacies and HCPs. Comparable Italian origin, HCP-channel, and botanical supplement emphasis to PharmExtracta.
• Erbozeta: Italian nutraceutical company with branded food supplement lines spanning gut health, gynecology, cardio-metabolic, and pediatrics. Comparable SKU breadth, Italian distribution, and HCP channel positioning to PharmExtracta.
• BioGaia: Swedish probiotics company developing proprietary Lactobacillus and Bifidobacterium strains for gastrointestinal, immune, and oral health, with strong clinical evidence base. Comparable to PharmExtracta's precision probiotic and Bacterial Care strategy.
• Pharmanutra: Italian nutraceutical company with a similar HCP-led commercial model, clinically validated branded supplements (notably the SiderAL iron and Cetilar musculoskeletal lines), and premium pharmacy positioning. Closest Italian listed analogue to PharmExtracta in go-to-market and category architecture.
• Pileje: France-based clinical nutrition and phytotherapy company built around HCP recommendation, proprietary probiotic strains, and condition-specific supplements (digestive, metabolic, women's health). Highly comparable to PharmExtracta in clinical positioning and pharmacy/HCP channel.
• Probi AB: Swedish probiotics R&D and B2B supplier specializing in proprietary, clinically documented probiotic strains for digestive and immune health. Comparable to PharmExtracta's strain-level R&D emphasis, though more B2B ingredient-supplier oriented.

Broad incumbents

• Novonesis (formerly Chr. Hansen): Global bioscience company with a substantial microbial and probiotic platform serving dietary supplement, infant nutrition, and pharma customers. Comparable at the probiotic strain and B2B ingredient layer; broader and more diversified than PharmExtracta.
• Recordati: Large Italian specialty pharmaceutical group with diversified branded pharmaceutical and consumer health portfolio including cardiovascular, metabolic, and rare disease products. Comparable Italy base and pharma execution model, but much broader scale; serves as a benchmark for how an Italian pharma-incumbent views the adjacent supplement market.

Emerging players

• Seed Health: US-based microbiome company commercializing clinically validated probiotic and synbiotic formulations across gut, vaginal, and pediatric health. Comparable category emphasis (microbiome-first, clinically substantiated, condition-specific SKUs), but younger, DTC-led, and US-centric rather than HCP-distributed in Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/pharmextractaspa
• LinkedInlinkedin.com/company/pharmextracta-spa
• Instagraminstagram.com/pharmextracta_spa

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmExtracta